Search Results for: Dalla presbifagia alla sarcopenia, il trattamento in medicina generale

Il secondo step sarà lavorare sull’accesso alle specializzazioni

Importante trattamento immediato; rischio malattia invasiva basso

In corsa quasi 80mila candidati per 14.787 posti, numeri in linea con l’anno scorso che però potrebbero salire nei prossimi mesi a 18-19mila.

Già da quest’anno +20-30% iscrivibili.Vera carenza su infermieri

Già da quest’anno +20-30% iscrivibili.Vera carenza su infermieri

Introduction
The nutritional status of patients with gastric cancer (GC) after total gastrectomy continues to deteriorate and lasts a long time after discharge, which is an independent risk factor for mortality. Recent guidelines have recommended appropriate nutritional support after discharge for cancer surgery patients with malnutrition or nutritional risk. The evidence on the efficacy of oral immunonutritional supplement (INS) and its effect on long-term disease-free survival (DFS) in patients with GC is limited. This study was designed to test the hypothesis that oral INS compared to diet alone may improve 3-year DFS of GC patients with pathological stage III after total gastrectomy (Nutrition Risk Screening 2002 score ≥3 at discharge).

Methods and analysis
This is a pragmatic, open-label, multicentre, randomised controlled study. 696 eligible GC patients with pathological stage III after total gastrectomy will be randomised in a 1:1 ratio to oral INS group or normal diet group for 6 months. The primary endpoint is 3-year DFS after discharge. The following secondary endpoints will be evaluated: 3-year overall survival; unplanned readmission rate at 3 and 6 months after discharge; quality of life, body mass index and haematological index at 3, 6 and 12 months after discharge; incidence of sarcopenia at 6 and 12 months after discharge; and the tolerance to chemotherapy. The adverse events of oral INS will also be evaluated during the intervention.

Ethics and dissemination
This study was approved by the ethics committee of Jinling Hospital, Nanjing University (number 2021NZKY-069-01). The present study may validate the effectiveness of oral immunonutritional therapy in improving 3-year DFS for GC patients with pathological stage III after total gastrectomy for the first time. The results of this trial will be disseminated in peer-reviewed journals and at scientific conferences.

Trial registration number
NCT05253716.

Rocca, particolarmente contento di eccellenza a Civitavecchia

Il ministro della Salute Schillaci annuncia di voler depenalizzare la responsabilità medica, tranne che per il dolo, e mantenendo solo quella civile

Per diagnosi e terapia alcune forme tumore, sclerosi e diabete

Prima terapia per mutazione che interessa 1% tumori polmonari